This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n19http://bibframe.org/vocab/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F11%3A10106142%21RIV12-MSM-11150___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F11%3A10106142%21RIV12-MSM-11150___
rdf:type
skos:Concept n11:Vysledek
rdfs:seeAlso
http://www.springerlink.com/content/p1083l5308018434/fulltext.pdf
dcterms:description
The study compared the pharmacokinetics, tissue distribution, and urinary excretion of platinum in rats after single oral doses of LA-12 and satraplatin. Characteristics of platinum exposure evaluated in the plasma, plasma ultrafiltrate and kidney and liver tissues. In the dose range of 37.5-300mg/kg, platinum concentrations increased less than in the proportion to the dose and, the fraction of dose exctreted in urine decreased. For both drugs, a dose-related decrease in the extent of oral bioavailability was observed most likely due to saturable intestinal absorption. The study compared the pharmacokinetics, tissue distribution, and urinary excretion of platinum in rats after single oral doses of LA-12 and satraplatin. Characteristics of platinum exposure evaluated in the plasma, plasma ultrafiltrate and kidney and liver tissues. In the dose range of 37.5-300mg/kg, platinum concentrations increased less than in the proportion to the dose and, the fraction of dose exctreted in urine decreased. For both drugs, a dose-related decrease in the extent of oral bioavailability was observed most likely due to saturable intestinal absorption.
dcterms:title
A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloro platinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloro platinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)
skos:prefLabel
A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloro platinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloro platinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)
skos:notation
RIV/00216208:11150/11:10106142!RIV12-MSM-11150___
n11:predkladatel
n17:orjk%3A11150
n5:aktivita
n9:V
n5:aktivity
V
n5:cisloPeriodika
6
n5:dodaniDat
n16:2012
n5:domaciTvurceVysledku
n8:4922417 n8:1802054
n5:druhVysledku
n12:J
n5:duvernostUdaju
n20:S
n5:entitaPredkladatele
n13:predkladatel
n5:idSjednocenehoVysledku
183681
n5:idVysledku
RIV/00216208:11150/11:10106142
n5:jazykVysledku
n14:eng
n5:klicovaSlova
Wistar rat; Pharmacokinetics; Platinum anti-cancer drugs
n5:klicoveSlovo
n6:Pharmacokinetics n6:Wistar%20rat n6:Platinum%20anti-cancer%20drugs
n5:kodStatuVydavatele
DE - Spolková republika Německo
n5:kontrolniKodProRIV
[3E77523D0880]
n5:nazevZdroje
Cancer Chemotherapy and Pharmacology
n5:obor
n7:FG
n5:pocetDomacichTvurcuVysledku
2
n5:pocetTvurcuVysledku
8
n5:rokUplatneniVysledku
n16:2011
n5:svazekPeriodika
67
n5:tvurceVysledku
Mistr, Adolf Chládková, Jiřina Hrušková, Veronika Kroutil, Aleš Chládek, Jaroslav Chlubnová, Hana Semerád, Martin Sova, Petr
n5:wos
000291036500004
s:issn
0344-5704
s:numberOfPages
10
n19:doi
10.1007/s00280-010-1411-0
n18:organizacniJednotka
11150